S-2.2, r. 2.1 - Minister’s Regulation under the Public Health Act

Section 16 Disposition versions

2019-10-17

16. A public health director performing an epidemiological investigation following a report or opinion received, as the case may be, under Chapter VIII or Chapter X of the Public Health Act (chapter S-2.2), sends to the Minister the following information:

(1)  the date of the beginning and end of the epidemiological investigation and its status;

(2)  the identification of the biological, chemical or physical agent, confirmed or suspected, responsible for the intoxication, infection or disease and, where applicable, a description of the circumstances that allowed its detection;

(3)  the identification of the biological, chemical or physical agent, confirmed or suspected, to which there was exposure;

(4)  the identification of the suspected or confirmed source of contamination, the method used to highlight it and the socio-sanitary region, province or State where the source is situated;

(5)  the result of environmental tests performed, including the sampling environment and the unit of measurement, the date on which the sample was taken and the date on which the result was received by the public health department;

(6)  in respect of the person covered by the investigation:

(a)  the description of the symptoms;

(b)  the sites of the infection or disease;

(c)  the clinical detection, the date on which it was carried out and the circumstances that led to the detection;

(d)  the classification of the disease;

(e)  the status, stage or form of the infection or disease;

(f)  an indication that it is a primary or secondary case;

(g)  an indication that it is a reinfection;

(h)  the concomitant and anterior diseases and infections, including, where the investigated disease is tuberculosis or an infection transmitted sexually and by blood, the status of the human immunodeficiency virus;

(i)  the results of any lung x-rays conducted;

(j)  a description of the treatment administered, its results and the level of compliance;

(k)  the name of every medication to which a sample taken from the person is resistant, its level of resistance and an indication that the resistance has been acquired or not during the treatment;

(l)  an indication of a failure of the treatment;

(m)  an indication that the person has been treated in a hyperbaric centre;

(n)  the date of any admission to a hospital centre operated by a health and social services institution, the duration of the stay and an indication that there has been a stay in the intensive care unit;

(o)  the evolution or final status of the infection or disease and the date on which the information has been obtained;

(p)  complications following the infection or disease and the date on which the information has been obtained;

(q)  the date of death of the person and an indication that the intoxication, infection or disease being investigated is a probable cause of death or not;

(r)  the profession of the person and the information concerning the sector of economic activity concerned;

(s)  a description of the living environment;

(t)  the identification of the risk factors associated to the infection or disease being investigated;

(u)  the ethno-cultural origin of the person, country of birth and date of arrival in Canada;

(v)  in the case of a woman, an indication that she is pregnant;

(w)  sex and the number of sexual partners reported;

(x)  an indication that the person uses drugs by injection or inhalation and the identification of those drugs;

(y)  an indication of the intentional nature of the exposure;

(z)  a history of the frequented circles where there was a risk of transmission;

(aa)  the commercial name of the vaccine administered before the infection or disease being investigated and connected to it, the lot number of the product, the dates and sites of the vaccination and the immunization status;

(bb)  the epidemiological link that corresponds to the unique number of the episode during which the person acquired the infection;

(7)  the identification of the probable or confirmed location of exposure or acquisition;

(8)  where the location of exposure or acquisition, probable or confirmed, is situated in Québec:

(a)  the name of the municipality and the identification of the socio-sanitary region, the local health and social services network and the territory of the local community service centre concerned by the exposure;

(b)  the geographical coordinates of the exposure;

(c)  in the case of a living environment or a building, its company or trade name, address and establishment number assigned in accordance with the Act respecting occupational health and safety (chapter S-2.1);

(9)  where the probable or confirmed location of exposure or acquisition is situated outside Québec, the travel history including the identification of the provinces or States visited;

(10)  where the acquisition is of a nosocomial nature:

(a)  an indication of the type of infection;

(b)  the public or private nature of the living environment in which the infection has been contracted and, in the case of a health and social services institution, the identification of the care unit;

(c)  the number of infectious sites, the observation period and the characteristics of the population affected;

(11)  in the case of carbon monoxide exposure, an indication of whether or not there was a carbon monoxide detector and the type of fuel involved;

(12)  the date of the probable or confirmed exposure;

(13)  the circumstances of the exposure, probable or confirmed, including the method, route and type of exposure;

(14)  in respect of any incident or outbreak investigated:

(a)  the start and end dates;

(b)  the date of the first data entry and the date of the last update;

(c)  the type of investigation;

(d)  the category of the outbreak and the socio-sanitary regions concerned;

(e)  the public health authority having taken charge of the investigation;

(f)  the disease, infection, intoxication or syndrome observed and the symptomatology observed or the case definition;

(g)  in respect of the persons concerned by the investigation:

i.  the number of cases by sex, age groups and the range of age of the persons concerned by the investigation;

ii.  the date of onset of the symptoms of the first and last cases;

iii.  the number of cases according to the incubation periods and the durations of the disease;

iv.  the number of probable, confirmed or suspected cases and, in the case of an exposure to a chemical agent, of cases where a significant exposure has been observed;

v.  the identification of any type of laboratory examination and the number of results;

vi.  the identification of any medication to which a sample taken from those persons is resistant, their number and level of resistance;

vii.  the number of cases according to the immunization status of the persons exposed and contacts;

viii.  the number of cases according to the evolution of the disease;

ix.  the number of cases according to the type of complication;

x.  the number of persons treated, hospitalized or deceased;

(h)  in respect of the exposure or transmission investigated:

i.  the identification of any probable or confirmed location of exposure, including the geographical coordinates, socio-sanitary region and province or State;

ii.  the number of persons exposed or the number of contacts, dates of exposure and type of contact or exposure;

iii.  the number of persons exposed based on the identification of the profession;

iv.  the type of transmission and contributing factors;

(i)  where the outbreak investigated is caused by influenza in a living environment in which care is provided:

i.  the public or private nature of the living environment in which the infection has been contracted and, in the case of a health and social services institution, the identification of the care unit;

ii.  the number of users and staff members exhibiting a flu-like and influenza syndrome and, among them, the number of persons vaccinated against influenza;

iii.  the number of users having received an antiviral prophylaxis, a description of the antiviral administered and, where applicable, the profile of the resistance encountered.

Where the investigation referred to in the first paragraph follows a report, the public health director sends the following information to the Minister, in addition to the information referred to in that paragraph:

(1)  the date and description of the report;

(2)  in respect of any person concerned by the investigation:

(a)  the unique file number assigned by the public health department to the person concerned by the investigation;

(b)  the person’s sex, date of birth and the address of the person’s residence including the socio-sanitary region;

(c)  the date of the onset of symptoms;

(d)  the type of sample taken, the site where it was taken, the date on which it was taken, the analyses carried out and the results obtained including the name of the pathogen and the biological indicator;

(e)  the name of the medical biology laboratory or a clinical department of laboratory medicine that carried out the analyses;

(f)  the unique code assigned by the laboratory to the analyses produced;

(g)  an indication that it is a probable, confirmed or suspected case or, in the case of an exposure to a chemical agent, that it is a case where a significant exposure has been observed;

(h)  information on blood, organ or tissue donations made by that person and information on the blood, blood products, organs or tissue received by that person;

(3)  the unique file number assigned by the public health department to the outbreak, incident or episode investigated.

M.O. 2019-012, s. 16.

Not in force

In force: 2019-10-17

16. A public health director performing an epidemiological investigation following a report or opinion received, as the case may be, under Chapter VIII or Chapter X of the Public Health Act (chapter S-2.2), sends to the Minister the following information:

(1)  the date of the beginning and end of the epidemiological investigation and its status;

(2)  the identification of the biological, chemical or physical agent, confirmed or suspected, responsible for the intoxication, infection or disease and, where applicable, a description of the circumstances that allowed its detection;

(3)  the identification of the biological, chemical or physical agent, confirmed or suspected, to which there was exposure;

(4)  the identification of the suspected or confirmed source of contamination, the method used to highlight it and the socio-sanitary region, province or State where the source is situated;

(5)  the result of environmental tests performed, including the sampling environment and the unit of measurement, the date on which the sample was taken and the date on which the result was received by the public health department;

(6)  in respect of the person covered by the investigation:

(a)  the description of the symptoms;

(b)  the sites of the infection or disease;

(c)  the clinical detection, the date on which it was carried out and the circumstances that led to the detection;

(d)  the classification of the disease;

(e)  the status, stage or form of the infection or disease;

(f)  an indication that it is a primary or secondary case;

(g)  an indication that it is a reinfection;

(h)  the concomitant and anterior diseases and infections, including, where the investigated disease is tuberculosis or an infection transmitted sexually and by blood, the status of the human immunodeficiency virus;

(i)  the results of any lung x-rays conducted;

(j)  a description of the treatment administered, its results and the level of compliance;

(k)  the name of every medication to which a sample taken from the person is resistant, its level of resistance and an indication that the resistance has been acquired or not during the treatment;

(l)  an indication of a failure of the treatment;

(m)  an indication that the person has been treated in a hyperbaric centre;

(n)  the date of any admission to a hospital centre operated by a health and social services institution, the duration of the stay and an indication that there has been a stay in the intensive care unit;

(o)  the evolution or final status of the infection or disease and the date on which the information has been obtained;

(p)  complications following the infection or disease and the date on which the information has been obtained;

(q)  the date of death of the person and an indication that the intoxication, infection or disease being investigated is a probable cause of death or not;

(r)  the profession of the person and the information concerning the sector of economic activity concerned;

(s)  a description of the living environment;

(t)  the identification of the risk factors associated to the infection or disease being investigated;

(u)  the ethno-cultural origin of the person, country of birth and date of arrival in Canada;

(v)  in the case of a woman, an indication that she is pregnant;

(w)  sex and the number of sexual partners reported;

(x)  an indication that the person uses drugs by injection or inhalation and the identification of those drugs;

(y)  an indication of the intentional nature of the exposure;

(z)  a history of the frequented circles where there was a risk of transmission;

(aa)  the commercial name of the vaccine administered before the infection or disease being investigated and connected to it, the lot number of the product, the dates and sites of the vaccination and the immunization status;

(bb)  the epidemiological link that corresponds to the unique number of the episode during which the person acquired the infection;

(7)  the identification of the probable or confirmed location of exposure or acquisition;

(8)  where the location of exposure or acquisition, probable or confirmed, is situated in Québec:

(a)  the name of the municipality and the identification of the socio-sanitary region, the local health and social services network and the territory of the local community service centre concerned by the exposure;

(b)  the geographical coordinates of the exposure;

(c)  in the case of a living environment or a building, its company or trade name, address and establishment number assigned in accordance with the Act respecting occupational health and safety (chapter S-2.1);

(9)  where the probable or confirmed location of exposure or acquisition is situated outside Québec, the travel history including the identification of the provinces or States visited;

(10)  where the acquisition is of a nosocomial nature:

(a)  an indication of the type of infection;

(b)  the public or private nature of the living environment in which the infection has been contracted and, in the case of a health and social services institution, the identification of the care unit;

(c)  the number of infectious sites, the observation period and the characteristics of the population affected;

(11)  in the case of carbon monoxide exposure, an indication of whether or not there was a carbon monoxide detector and the type of fuel involved;

(12)  the date of the probable or confirmed exposure;

(13)  the circumstances of the exposure, probable or confirmed, including the method, route and type of exposure;

(14)  in respect of any incident or outbreak investigated:

(a)  the start and end dates;

(b)  the date of the first data entry and the date of the last update;

(c)  the type of investigation;

(d)  the category of the outbreak and the socio-sanitary regions concerned;

(e)  the public health authority having taken charge of the investigation;

(f)  the disease, infection, intoxication or syndrome observed and the symptomatology observed or the case definition;

(g)  in respect of the persons concerned by the investigation:

i.  the number of cases by sex, age groups and the range of age of the persons concerned by the investigation;

ii.  the date of onset of the symptoms of the first and last cases;

iii.  the number of cases according to the incubation periods and the durations of the disease;

iv.  the number of probable, confirmed or suspected cases and, in the case of an exposure to a chemical agent, of cases where a significant exposure has been observed;

v.  the identification of any type of laboratory examination and the number of results;

vi.  the identification of any medication to which a sample taken from those persons is resistant, their number and level of resistance;

vii.  the number of cases according to the immunization status of the persons exposed and contacts;

viii.  the number of cases according to the evolution of the disease;

ix.  the number of cases according to the type of complication;

x.  the number of persons treated, hospitalized or deceased;

(h)  in respect of the exposure or transmission investigated:

i.  the identification of any probable or confirmed location of exposure, including the geographical coordinates, socio-sanitary region and province or State;

ii.  the number of persons exposed or the number of contacts, dates of exposure and type of contact or exposure;

iii.  the number of persons exposed based on the identification of the profession;

iv.  the type of transmission and contributing factors;

(i)  where the outbreak investigated is caused by influenza in a living environment in which care is provided:

i.  the public or private nature of the living environment in which the infection has been contracted and, in the case of a health and social services institution, the identification of the care unit;

ii.  the number of users and staff members exhibiting a flu-like and influenza syndrome and, among them, the number of persons vaccinated against influenza;

iii.  the number of users having received an antiviral prophylaxis, a description of the antiviral administered and, where applicable, the profile of the resistance encountered.

Where the investigation referred to in the first paragraph follows a report, the public health director sends the following information to the Minister, in addition to the information referred to in that paragraph:

(1)  the date and description of the report;

(2)  in respect of any person concerned by the investigation:

(a)  the unique file number assigned by the public health department to the person concerned by the investigation;

(b)  the person’s sex, date of birth and the address of the person’s residence including the socio-sanitary region;

(c)  the date of the onset of symptoms;

(d)  the type of sample taken, the site where it was taken, the date on which it was taken, the analyses carried out and the results obtained including the name of the pathogen and the biological indicator;

(e)  the name of the medical biology laboratory or a clinical department of laboratory medicine that carried out the analyses;

(f)  the unique code assigned by the laboratory to the analyses produced;

(g)  an indication that it is a probable, confirmed or suspected case or, in the case of an exposure to a chemical agent, that it is a case where a significant exposure has been observed;

(h)  information on blood, organ or tissue donations made by that person and information on the blood, blood products, organs or tissue received by that person;

(3)  the unique file number assigned by the public health department to the outbreak, incident or episode investigated.

M.O. 2019-012, s. 16.